Co-Authors
This is a "connection" page, showing publications co-authored by Ravi Salgia and Hedy Kindler.
Connection Strength
1.638
-
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis. 2019 Sep 04; 8(9):49.
Score: 0.188
-
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327.
Score: 0.170
-
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
Score: 0.153
-
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep. 2016 Apr 15; 6:24578.
Score: 0.149
-
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
Score: 0.144
-
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919.
Score: 0.134
-
Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. BMJ Open. 2012; 2(5).
Score: 0.117
-
Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism. J Carcinog. 2011 Mar 03; 10:4.
Score: 0.105
-
Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8.
Score: 0.088
-
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
Score: 0.073
-
Development of response criteria for mesothelioma based on a mathematical model. J Clin Oncol. 2005 Jun; 23(16_suppl):7176.
Score: 0.070
-
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
Score: 0.047
-
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667.
Score: 0.044
-
Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012; 7(9):e45330.
Score: 0.029
-
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2012 Oct; 94(4):1086-92.
Score: 0.029
-
Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. Int Surg. 2012 Jan-Mar; 97(1):65-70.
Score: 0.028
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.027
-
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14.
Score: 0.022
-
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):549-58.
Score: 0.020